Loading
A phase 3 trial of Tebentafusp, Pembrolizumab in melanoma, run by Immunocore Ltd, now recruiting.
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) is a phase 3 interventional study registered as NCT05549297 by Immunocore Ltd, with 540 participants planned, started 2022-12-19 and due to reach its primary completion in 2028-03. Interventions recorded: Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice. Conditions listed: Advanced Melanoma. No results are recorded here; the registry entry is the source.
Shares Immunocore, Tebentafusp, T-cell engagers (bispecific), Pembrolizumab.
Shares Immunocore, Advanced melanoma (unresectable stage III and stage IV), T-cell engagers (bispecific), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares TCR-T cell therapy, Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab.